Share Price and Basic Stock Data
Last Updated: February 2, 2026, 4:38 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Vaishali Pharma Ltd operates in the pharmaceutical sector, with a market capitalization of ₹107 Cr and a share price of ₹8.22. The company’s revenue has shown significant fluctuations over recent quarters. For instance, sales reported in March 2023 stood at ₹70 Cr, while the trailing twelve months (TTM) revenue reached ₹117 Cr. The quarterly sales peaked at ₹32.40 Cr in March 2024, indicating a recovery from lower figures of ₹12.57 Cr in September 2023 and ₹13.42 Cr in June 2023. This volatility suggests that the company is navigating a challenging market environment. The overall trend indicates a potential rebound as sales moved up to ₹27.90 Cr in December 2023, indicating seasonal variations or strategic adjustments in their product offerings. A focus on operational efficiency and market positioning could contribute to stabilizing revenue in the coming quarters, although the company faces intense competitive pressures typical in the pharmaceutical industry.
Profitability and Efficiency Metrics
Vaishali Pharma’s profitability metrics exhibit considerable variability. The operating profit margin (OPM) stood at 4.16%, which is below the industry average, indicating challenges in managing costs effectively. Notably, the OPM has fluctuated significantly, with a peak of 21.08% in September 2023, followed by declines to 4.87% in December 2024. The company reported a net profit of ₹1.18 Cr for September 2025, with an earnings per share (EPS) of ₹0.09. However, the reported net profit has been inconsistent, with a loss of ₹4.68 Cr in March 2024. The interest coverage ratio (ICR) is at 2.08x, suggesting that while the company can cover its interest expenses, its profitability remains constrained. The return on equity (ROE) is low at 1.52%, highlighting the need for enhanced operational efficiency to improve shareholder returns.
Balance Sheet Strength and Financial Ratios
Vaishali Pharma’s balance sheet reflects a cautious financial position with total borrowings of ₹16 Cr against reserves of ₹41 Cr. The company has maintained a low long-term debt to equity ratio of 0.06, indicating a conservative approach to leveraging. Current assets are supported by a strong current ratio of 2.61, which suggests good short-term financial health. However, the price-to-book value (P/BV) ratio stood at 2.53x, indicating a premium valuation relative to its book value per share of ₹4.98. The cash conversion cycle (CCC) is at 77 days, which is relatively high, potentially indicating inefficiencies in inventory management. The return on capital employed (ROCE) is also low at 4.93%, suggesting that the company is not utilizing its capital effectively to generate profits. These factors combined indicate a need for strategic financial management to enhance overall efficiency and profitability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Vaishali Pharma Ltd reveals a relatively stable distribution, with promoters holding 26.32% of the shares, while public shareholders account for 73.68%. The number of shareholders increased significantly from 9,983 in September 2023 to 27,752 by September 2025, indicating growing investor interest. However, foreign institutional investors (FIIs) hold no stake, which may reflect a lack of confidence from larger investors in the company’s growth prospects. This absence of institutional backing could hinder the stock’s liquidity and valuation. Additionally, the consistent promoter shareholding indicates a level of commitment to the company, yet the lack of significant institutional investment may limit broader market support. The investor sentiment appears mixed, influenced by the company’s fluctuating performance and the overall market conditions.
Outlook, Risks, and Final Insight
Looking ahead, Vaishali Pharma faces both opportunities and challenges. The recovery in sales trends and operational adjustments may provide a pathway to improved profitability. However, the volatility in profit margins and inconsistent net profits present significant risks. The company’s ability to manage costs effectively and enhance operational efficiency will be critical for sustainable growth. Additionally, without the backing of institutional investors, the stock may continue to experience volatility, impacting investor confidence. Strategic initiatives aimed at stabilizing revenue and improving margins could position the company favorably in the long term. Nonetheless, external factors such as regulatory changes and market competition will continue to pose risks. A focused approach towards strengthening financial health and operational capabilities will be essential for Vaishali Pharma to navigate these challenges successfully.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujarat Metallic Coal & Coke Ltd | 5.94 Cr. | 30.0 | / | 77.6 | 0.00 % | 0.37 % | 2.00 % | 100 | |
| Gensol Engineering Ltd | 113 Cr. | 29.4 | 751/20.5 | 1.10 | 155 | 0.00 % | 14.3 % | 22.4 % | 10.0 |
| Fusion Micro Finance Ltd | 2,900 Cr. | 180 | 212/124 | 118 | 0.00 % | 2.96 % | 54.5 % | 10.0 | |
| Five X Tradecom Ltd | 0.99 Cr. | 0.48 | / | 9.35 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| East West Holdings Ltd | 36.9 Cr. | 2.89 | 7.43/2.70 | 4.93 | 0.00 % | 6.98 % | 0.86 % | 2.00 | |
| Industry Average | 6,477.92 Cr | 205.50 | 322.07 | 219.29 | 0.27% | 11.73% | 22.92% | 9.00 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.16 | 20.09 | 26.24 | 13.42 | 12.57 | 27.90 | 32.40 | 18.08 | 20.79 | 27.91 | 32.25 | 23.75 | 33.45 |
| Expenses | 10.57 | 16.53 | 25.46 | 11.11 | 9.92 | 24.95 | 39.19 | 15.73 | 18.37 | 26.55 | 38.29 | 22.38 | 32.06 |
| Operating Profit | 2.59 | 3.56 | 0.78 | 2.31 | 2.65 | 2.95 | -6.79 | 2.35 | 2.42 | 1.36 | -6.04 | 1.37 | 1.39 |
| OPM % | 19.68% | 17.72% | 2.97% | 17.21% | 21.08% | 10.57% | -20.96% | 13.00% | 11.64% | 4.87% | -18.73% | 5.77% | 4.16% |
| Other Income | 0.74 | 0.53 | 0.53 | 0.36 | 0.30 | 0.47 | 0.91 | 0.42 | 0.71 | 1.07 | 1.00 | 0.84 | 0.84 |
| Interest | 0.53 | 0.42 | 0.54 | 0.43 | 0.47 | 0.43 | 0.40 | 0.38 | 0.38 | 0.38 | 0.44 | 0.33 | 0.40 |
| Depreciation | 0.14 | 0.12 | 0.15 | 0.12 | 0.12 | 0.12 | 0.14 | 0.12 | 0.12 | 0.12 | 0.12 | 0.14 | 0.17 |
| Profit before tax | 2.66 | 3.55 | 0.62 | 2.12 | 2.36 | 2.87 | -6.42 | 2.27 | 2.63 | 1.93 | -5.60 | 1.74 | 1.66 |
| Tax % | 24.81% | 25.07% | 29.03% | 25.00% | 27.97% | 26.13% | -26.95% | 25.11% | 25.10% | 24.87% | -23.39% | 26.44% | 28.31% |
| Net Profit | 1.99 | 2.66 | 0.44 | 1.59 | 1.70 | 2.11 | -4.68 | 1.70 | 1.97 | 1.44 | -4.29 | 1.28 | 1.18 |
| EPS in Rs | 0.19 | 0.25 | 0.04 | 0.15 | 0.16 | 0.20 | -0.44 | 0.16 | 0.18 | 0.13 | -0.40 | 0.12 | 0.09 |
Last Updated: December 28, 2025, 3:31 pm
Below is a detailed analysis of the quarterly data for Vaishali Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 33.45 Cr.. The value appears strong and on an upward trend. It has increased from 23.75 Cr. (Jun 2025) to 33.45 Cr., marking an increase of 9.70 Cr..
- For Expenses, as of Sep 2025, the value is 32.06 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 22.38 Cr. (Jun 2025) to 32.06 Cr., marking an increase of 9.68 Cr..
- For Operating Profit, as of Sep 2025, the value is 1.39 Cr.. The value appears strong and on an upward trend. It has increased from 1.37 Cr. (Jun 2025) to 1.39 Cr., marking an increase of 0.02 Cr..
- For OPM %, as of Sep 2025, the value is 4.16%. The value appears to be declining and may need further review. It has decreased from 5.77% (Jun 2025) to 4.16%, marking a decrease of 1.61%.
- For Other Income, as of Sep 2025, the value is 0.84 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.84 Cr..
- For Interest, as of Sep 2025, the value is 0.40 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.33 Cr. (Jun 2025) to 0.40 Cr., marking an increase of 0.07 Cr..
- For Depreciation, as of Sep 2025, the value is 0.17 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.14 Cr. (Jun 2025) to 0.17 Cr., marking an increase of 0.03 Cr..
- For Profit before tax, as of Sep 2025, the value is 1.66 Cr.. The value appears to be declining and may need further review. It has decreased from 1.74 Cr. (Jun 2025) to 1.66 Cr., marking a decrease of 0.08 Cr..
- For Tax %, as of Sep 2025, the value is 28.31%. The value appears to be increasing, which may not be favorable. It has increased from 26.44% (Jun 2025) to 28.31%, marking an increase of 1.87%.
- For Net Profit, as of Sep 2025, the value is 1.18 Cr.. The value appears to be declining and may need further review. It has decreased from 1.28 Cr. (Jun 2025) to 1.18 Cr., marking a decrease of 0.10 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.09. The value appears to be declining and may need further review. It has decreased from 0.12 (Jun 2025) to 0.09, marking a decrease of 0.03.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:26 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 121 | 95 | 67 | 64 | 68 | 75 | 60 | 54 | 76 | 70 | 86 | 99 | 117 |
| Expenses | 118 | 95 | 66 | 60 | 65 | 73 | 59 | 51 | 69 | 60 | 85 | 98 | 119 |
| Operating Profit | 2 | -0 | 1 | 3 | 3 | 2 | 1 | 3 | 7 | 9 | 2 | 1 | -2 |
| OPM % | 2% | -0% | 1% | 5% | 4% | 3% | 2% | 5% | 9% | 13% | 2% | 1% | -2% |
| Other Income | 1 | 4 | 3 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Profit before tax | 1 | 0 | -0 | 1 | 1 | 1 | 0 | 1 | 6 | 9 | 1 | 1 | -0 |
| Tax % | 50% | -7% | 300% | 32% | 41% | 37% | 62% | 26% | 30% | 25% | 23% | 34% | |
| Net Profit | 0 | 0 | -0 | 1 | 1 | 1 | 0 | 1 | 4 | 7 | 1 | 1 | -0 |
| EPS in Rs | 0.38 | 0.20 | -0.04 | 0.15 | 0.08 | 0.07 | 0.00 | 0.10 | 0.38 | 0.63 | 0.07 | 0.08 | -0.06 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | -100.00% | 300.00% | 75.00% | -85.71% | 0.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | -100.00% | 400.00% | -225.00% | -160.71% | 85.71% |
Vaishali Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 11% |
| 3 Years: | 9% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 94% |
| 3 Years: | -41% |
| TTM: | -52% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 8% |
| 1 Year: | -35% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 8% |
| 3 Years: | 6% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 1:50 pm
Balance Sheet
Last Updated: December 10, 2025, 3:37 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.50 | 0.50 | 0.50 | 3 | 7 | 7 | 11 | 11 | 11 | 11 | 11 | 26 | 26 |
| Reserves | 3 | 3 | 3 | 1 | 14 | 15 | 11 | 12 | 16 | 30 | 32 | 39 | 41 |
| Borrowings | 19 | 25 | 21 | 23 | 18 | 17 | 17 | 18 | 21 | 15 | 13 | 12 | 16 |
| Other Liabilities | 32 | 17 | 25 | 18 | 25 | 30 | 28 | 46 | 34 | 24 | 24 | 33 | 39 |
| Total Liabilities | 53 | 46 | 49 | 45 | 64 | 69 | 66 | 86 | 82 | 79 | 80 | 110 | 122 |
| Fixed Assets | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Other Assets | 53 | 44 | 48 | 43 | 62 | 67 | 64 | 84 | 80 | 76 | 77 | 107 | 114 |
| Total Assets | 53 | 46 | 49 | 45 | 64 | 69 | 66 | 86 | 82 | 79 | 80 | 110 | 122 |
Below is a detailed analysis of the balance sheet data for Vaishali Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 26.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 26.00 Cr..
- For Reserves, as of Sep 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 39.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 2.00 Cr..
- For Borrowings, as of Sep 2025, the value is 16.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 12.00 Cr. (Mar 2025) to 16.00 Cr., marking an increase of 4.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 39.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 33.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 6.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 122.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 110.00 Cr. (Mar 2025) to 122.00 Cr., marking an increase of 12.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 5.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 5.00 Cr., marking an increase of 5.00 Cr..
- For Other Assets, as of Sep 2025, the value is 114.00 Cr.. The value appears strong and on an upward trend. It has increased from 107.00 Cr. (Mar 2025) to 114.00 Cr., marking an increase of 7.00 Cr..
- For Total Assets, as of Sep 2025, the value is 122.00 Cr.. The value appears strong and on an upward trend. It has increased from 110.00 Cr. (Mar 2025) to 122.00 Cr., marking an increase of 12.00 Cr..
Notably, the Reserves (41.00 Cr.) exceed the Borrowings (16.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -17.00 | -25.00 | -20.00 | -20.00 | -15.00 | -15.00 | -16.00 | -15.00 | -14.00 | -6.00 | -11.00 | -11.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 116 | 133 | 221 | 214 | 240 | 240 | 286 | 453 | 282 | 281 | 209 | 172 |
| Inventory Days | 26 | 13 | 20 | 7 | 11 | 5 | 6 | 5 | 4 | 20 | 2 | 20 |
| Days Payable | 99 | 66 | 145 | 100 | 136 | 130 | 169 | 321 | 163 | 120 | 95 | 116 |
| Cash Conversion Cycle | 43 | 80 | 96 | 121 | 115 | 115 | 123 | 137 | 122 | 181 | 116 | 77 |
| Working Capital Days | 59 | 98 | 25 | 14 | 97 | 98 | 124 | 146 | 111 | 208 | 169 | 231 |
| ROCE % | 19% | 14% | 13% | 16% | 13% | 10% | 7% | 10% | 19% | 22% | 6% | 5% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.06 | 0.68 | 6.26 | 3.82 | 0.99 |
| Diluted EPS (Rs.) | 0.06 | 0.64 | 5.91 | 3.82 | 0.99 |
| Cash EPS (Rs.) | 0.09 | 1.14 | 6.74 | 4.25 | 1.40 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 4.98 | 33.41 | 31.26 | 24.99 | 21.26 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 4.98 | 33.41 | 31.26 | 24.99 | 21.26 |
| Revenue From Operations / Share (Rs.) | 7.59 | 80.49 | 66.05 | 71.89 | 50.99 |
| PBDIT / Share (Rs.) | 0.25 | 2.96 | 10.77 | 8.20 | 4.21 |
| PBIT / Share (Rs.) | 0.21 | 2.48 | 10.29 | 7.76 | 3.81 |
| PBT / Share (Rs.) | 0.09 | 0.86 | 8.39 | 5.43 | 1.33 |
| Net Profit / Share (Rs.) | 0.06 | 0.67 | 6.26 | 3.81 | 0.99 |
| PBDIT Margin (%) | 3.32 | 3.67 | 16.30 | 11.39 | 8.26 |
| PBIT Margin (%) | 2.83 | 3.08 | 15.58 | 10.79 | 7.46 |
| PBT Margin (%) | 1.23 | 1.07 | 12.69 | 7.55 | 2.61 |
| Net Profit Margin (%) | 0.82 | 0.83 | 9.47 | 5.30 | 1.94 |
| Return on Networth / Equity (%) | 1.25 | 2.00 | 20.02 | 15.26 | 4.66 |
| Return on Capital Employeed (%) | 4.02 | 5.68 | 23.17 | 27.57 | 14.94 |
| Return On Assets (%) | 0.74 | 0.89 | 8.36 | 4.92 | 1.21 |
| Long Term Debt / Equity (X) | 0.06 | 0.10 | 0.15 | 0.11 | 0.18 |
| Total Debt / Equity (X) | 0.17 | 0.35 | 0.41 | 0.78 | 0.71 |
| Asset Turnover Ratio (%) | 1.04 | 1.09 | 0.86 | 0.90 | 0.70 |
| Current Ratio (X) | 2.61 | 2.25 | 2.27 | 1.47 | 1.37 |
| Quick Ratio (X) | 2.49 | 2.24 | 2.17 | 1.46 | 1.36 |
| Inventory Turnover Ratio (X) | 38.16 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 2.08 | 1.83 | 5.66 | 3.52 | 1.70 |
| Interest Coverage Ratio (Post Tax) (X) | 1.52 | 1.41 | 4.29 | 2.64 | 1.40 |
| Enterprise Value (Cr.) | 173.94 | 161.15 | 166.55 | 89.17 | 49.85 |
| EV / Net Operating Revenue (X) | 1.76 | 1.87 | 2.39 | 1.18 | 0.92 |
| EV / EBITDA (X) | 52.78 | 50.82 | 14.66 | 10.32 | 11.22 |
| MarketCap / Net Operating Revenue (X) | 1.66 | 1.74 | 2.21 | 0.92 | 0.63 |
| Price / BV (X) | 2.53 | 4.19 | 4.67 | 2.65 | 1.53 |
| Price / Net Operating Revenue (X) | 1.66 | 1.74 | 2.21 | 0.92 | 0.63 |
| EarningsYield | 0.00 | 0.00 | 0.04 | 0.05 | 0.03 |
After reviewing the key financial ratios for Vaishali Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 10.00 (Mar 24) to 2.00, marking a decrease of 8.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.68 (Mar 24) to 0.06, marking a decrease of 0.62.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.64 (Mar 24) to 0.06, marking a decrease of 0.58.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 3. It has decreased from 1.14 (Mar 24) to 0.09, marking a decrease of 1.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 4.98. It has decreased from 33.41 (Mar 24) to 4.98, marking a decrease of 28.43.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 4.98. It has decreased from 33.41 (Mar 24) to 4.98, marking a decrease of 28.43.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 7.59. It has decreased from 80.49 (Mar 24) to 7.59, marking a decrease of 72.90.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 2. It has decreased from 2.96 (Mar 24) to 0.25, marking a decrease of 2.71.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.21. This value is within the healthy range. It has decreased from 2.48 (Mar 24) to 0.21, marking a decrease of 2.27.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has decreased from 0.86 (Mar 24) to 0.09, marking a decrease of 0.77.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 2. It has decreased from 0.67 (Mar 24) to 0.06, marking a decrease of 0.61.
- For PBDIT Margin (%), as of Mar 25, the value is 3.32. This value is below the healthy minimum of 10. It has decreased from 3.67 (Mar 24) to 3.32, marking a decrease of 0.35.
- For PBIT Margin (%), as of Mar 25, the value is 2.83. This value is below the healthy minimum of 10. It has decreased from 3.08 (Mar 24) to 2.83, marking a decrease of 0.25.
- For PBT Margin (%), as of Mar 25, the value is 1.23. This value is below the healthy minimum of 10. It has increased from 1.07 (Mar 24) to 1.23, marking an increase of 0.16.
- For Net Profit Margin (%), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 5. It has decreased from 0.83 (Mar 24) to 0.82, marking a decrease of 0.01.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 15. It has decreased from 2.00 (Mar 24) to 1.25, marking a decrease of 0.75.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.02. This value is below the healthy minimum of 10. It has decreased from 5.68 (Mar 24) to 4.02, marking a decrease of 1.66.
- For Return On Assets (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 5. It has decreased from 0.89 (Mar 24) to 0.74, marking a decrease of 0.15.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.10 (Mar 24) to 0.06, marking a decrease of 0.04.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has decreased from 0.35 (Mar 24) to 0.17, marking a decrease of 0.18.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.04. It has decreased from 1.09 (Mar 24) to 1.04, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 2.25 (Mar 24) to 2.61, marking an increase of 0.36.
- For Quick Ratio (X), as of Mar 25, the value is 2.49. This value exceeds the healthy maximum of 2. It has increased from 2.24 (Mar 24) to 2.49, marking an increase of 0.25.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 38.16. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 38.16, marking an increase of 38.16.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.08. This value is below the healthy minimum of 3. It has increased from 1.83 (Mar 24) to 2.08, marking an increase of 0.25.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.52. This value is below the healthy minimum of 3. It has increased from 1.41 (Mar 24) to 1.52, marking an increase of 0.11.
- For Enterprise Value (Cr.), as of Mar 25, the value is 173.94. It has increased from 161.15 (Mar 24) to 173.94, marking an increase of 12.79.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.76. This value is within the healthy range. It has decreased from 1.87 (Mar 24) to 1.76, marking a decrease of 0.11.
- For EV / EBITDA (X), as of Mar 25, the value is 52.78. This value exceeds the healthy maximum of 15. It has increased from 50.82 (Mar 24) to 52.78, marking an increase of 1.96.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.66. This value is within the healthy range. It has decreased from 1.74 (Mar 24) to 1.66, marking a decrease of 0.08.
- For Price / BV (X), as of Mar 25, the value is 2.53. This value is within the healthy range. It has decreased from 4.19 (Mar 24) to 2.53, marking a decrease of 1.66.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.66. This value is within the healthy range. It has decreased from 1.74 (Mar 24) to 1.66, marking a decrease of 0.08.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vaishali Pharma Ltd:
- Net Profit Margin: 0.82%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.02% (Industry Average ROCE: 11.73%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.25% (Industry Average ROE: 22.92%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.52
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.49
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 322.07)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.17
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.82%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 706 to 709, 7th Floor, Aravali Business Center, Mumbai Maharashtra 400092 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Atul Arvind Vasani | Chairman & Managing Director |
| Mr. Dewansh Ajay Vasani | Executive Director & CFO |
| Mrs. Jagruti Atul Vasani | Whole Time Director |
| Mr. Manish Bhagwandas Ved | Ind. Non-Executive Director |
| Mr. Pratik Vikram Jakhelia | Ind. Non-Executive Director |
| Mr. Bhaveshkumar Upadhyay | Non Exe.Non Ind.Director |
FAQ
What is the intrinsic value of Vaishali Pharma Ltd?
Vaishali Pharma Ltd's intrinsic value (as of 05 February 2026) is ₹0.89 which is 88.81% lower the current market price of ₹7.95, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹104 Cr. market cap, FY2025-2026 high/low of ₹18.8/7.40, reserves of ₹41 Cr, and liabilities of ₹122 Cr.
What is the Market Cap of Vaishali Pharma Ltd?
The Market Cap of Vaishali Pharma Ltd is 104 Cr..
What is the current Stock Price of Vaishali Pharma Ltd as on 05 February 2026?
The current stock price of Vaishali Pharma Ltd as on 05 February 2026 is ₹7.95.
What is the High / Low of Vaishali Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Vaishali Pharma Ltd stocks is ₹18.8/7.40.
What is the Stock P/E of Vaishali Pharma Ltd?
The Stock P/E of Vaishali Pharma Ltd is .
What is the Book Value of Vaishali Pharma Ltd?
The Book Value of Vaishali Pharma Ltd is 5.16.
What is the Dividend Yield of Vaishali Pharma Ltd?
The Dividend Yield of Vaishali Pharma Ltd is 0.00 %.
What is the ROCE of Vaishali Pharma Ltd?
The ROCE of Vaishali Pharma Ltd is 4.93 %.
What is the ROE of Vaishali Pharma Ltd?
The ROE of Vaishali Pharma Ltd is 1.52 %.
What is the Face Value of Vaishali Pharma Ltd?
The Face Value of Vaishali Pharma Ltd is 2.00.